Compare ALLO & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | DOUG |
|---|---|---|
| Founded | 2017 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 219.1M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | DOUG |
|---|---|---|
| Price | $1.48 | $2.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $8.27 | N/A |
| AVG Volume (30 Days) | ★ 4.6M | 531.2K |
| Earning Date | 03-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,030,928,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.67 |
| 52 Week Low | $0.86 | $1.48 |
| 52 Week High | $3.78 | $3.20 |
| Indicator | ALLO | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 55.98 |
| Support Level | $1.54 | $2.51 |
| Resistance Level | $1.83 | $2.78 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 25.23 | 55.41 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.